Compare Sony Group Corp (SONY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs TG Therapeutics Inc — how do they compare? Sony Group Corp trades at $23.06 (market cap $138.43B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Sony Group Corp is far larger — about 18.1× TG Therapeutics Inc's market cap, and Sony Group Corp pays a 0.67% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SONY | TGTX | |
|---|---|---|
Market Cap | $138.43B | $7.64B |
Sector | Technology | Health |
52-Week High | $30.26 | $59.06 |
52-Week Low | $19.32 | $26.94 |
Enterprise Value | $136.35B | $7.84B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony's stock trades at $23.54, down 1.18% over 24 hours, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent earnings show mixed quarterly beats, with Q2 2026 EPS of $0.36 exceeding expectations. The company reported strong 2025 fundamentals, including $12.96T revenue and $1.14T net income, though 2026 projections indicate a net loss. Positive sentiment is driven by blockbuster film success, such as Spider-Man: Brand New Day, and a joint venture with TSMC for image sensors, highlighting growth in entertainment and technology segments.
Sony presents a favorable outlook with analyst consensus strongly bullish (68.75% buy ratings) and a potential 29.75% upside. Key opportunities include robust gaming and sensor divisions, but risks involve 2026 profit margin pressures, competitive threats, and execution challenges in new ventures. Investors should weigh solid cash flow and asset base against near-term earnings volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
